Time of Harvest and Wine Quality of Esprit Wine Grapes

Currently there is little to no information regarding when to harvest many of the coldhardy hybrid grape cultivars. There are contrasting opinions of the quality of the wine made from some of these cultivars, which may in part be due to a difference in timing of harvest. Many of the cold hardy cultivars contain Vitis labrusca in their parentage that can lead to differing levels of ‘foxy’ flavors depending on when the fruit is harvested. Wineries may prefer different levels of the typical V. labrusca flavors in their wines. Many of the cold-hardy cultivars also tend to have high titratable acidity (TA) and harvest is delayed to lower the TA. It is unknown what impact a later harvest has on other parameters of fruit quality. The objective of this study was to evaluate the quality attributes of the wine made from the grape cultivar Esprit harvested earlier and later than the traditional harvest date

Dirac Gauginos, Negative Supertraces and Gauge Mediation

In an attempt to maximize General Gauge Mediated parameter space, I propose simple models in which gauginos and scalars are generated from disconnected mechanisms. In my models Dirac gauginos are generated through the supersoft mechanism, while independent R-symmetric scalar masses are generated through operators involving non-zero messenger supertrace. I propose several new methods for generating negative messenger supertraces which result in viable positive mass squareds for MSSM scalars. The resultant spectra are novel, compressed and may contain light fermionic SM adjoint fields.Comment: 16 pages 3 figure

D-type supersymmetry breaking and brane-to-brane gravity mediation

We revisit the issue of gravitational contributions to soft masses in five-dimensional sequestered models. We point out that, unlike for the case of F-type supersymmetry breaking, for D-type breaking these effects generically give positive soft masses squared for the sfermions. This drastically improves model building. We discuss the phenomenological implications of our result.Comment: 16 pages. Typos corrected, minor clarifications. To be published in Phys. Lett.

Minimally Fine-Tuned Supersymmetric Standard Models with Intermediate-Scale Supersymmetry Breaking

We construct realistic supersymmetric theories in which the correct scale for electroweak symmetry breaking is obtained without significant fine-tuning. We consider two classes of models. In one class supersymmetry breaking is transmitted to the supersymmetric standard model sector through Dirac gaugino mass terms generated by a D-term vacuum expectation value of a U(1) gauge field. In the other class the supersymmetry breaking sector is separated from the supersymmetric standard model sector in an extra dimension, and the transmission of supersymmetry breaking occurs through gauge mediation. In both these theories the Higgs sector contains two Higgs doublets and a singlet, but unlike the case for the next-to-minimal supersymmetric standard model the singlet field is not responsible for generating the supersymmetric or supersymmetry breaking mass for the Higgs doublets. These masses, as well as the mass for the singlet, are generated through gravitational-strength interactions. The scale at which the squark and slepton masses are generated is of order (1-100) TeV, and the generated masses do not respect the unified mass relations. We find that electroweak symmetry breaking in these theories is caused by an interplay between the top-stop radiative correction and the holomorphic supersymmetry breaking mass for the Higgs doublets and that the fine-tuning can be reduced to the level of 20%. The theories have rich phenomenology, including a variety of possibilities for the lightest supersymmetric particle.Comment: 24 pages, version to appear in Nucl. Phys.

Arbaclofen in fragile X syndrome: results of phase 3 trials

Background: Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of the study is to determine safety and efficacy of arbaclofen for social avoidance in FXS. Methods: Two phase 3 placebo-controlled trials were conducted, a flexible dose trial in subjects age 12-50 (209FX301, adolescent/adult study) and a fixed dose trial in subjects age 5-11 (209FX302, child study). The primary endpoint for both trials was the Social Avoidance subscale of the Aberrant Behavior Checklist-Community Edition, FXS-specific (ABC-C FX ). Secondary outcomes included other ABC-C FX subscale scores, Clinical Global Impression-Improvement (CGI-I), Clinical Global Impression-Severity (CGI-S), and Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Socialization domain score. Results: A total 119 of 125 randomized subjects completed the adolescent/adult study (n = 57 arbaclofen, 62 placebo) and 159/172 completed the child study (arbaclofen 5 BID n = 38; 10 BID n = 39; 10 TID n = 38; placebo n = 44). There were no serious adverse events (AEs); the most common AEs included somatic (headache, vomiting, nausea), neurobehavioral (irritability/agitation, anxiety, hyperactivity), decreased appetite, and infectious conditions, many of which were also common on placebo. In the combined studies, there were 13 discontinuations (n = 12 arbaclofen, 1 placebo) due to AEs (all neurobehavioral). The adolescent/adult study did not show benefit for arbaclofen over placebo for any measure. In the child study, the highest dose group showed benefit over placebo on the ABC-C FX Irritability subscale (p = 0.03) and Parenting Stress Index (PSI, p = 0.03) and trends toward benefit on the ABC-C FX Social Avoidance and Hyperactivity subscales (both p < 0.1) and CGI-I (p = 0.119). Effect size in the highest dose group was similar to effect sizes for FDA-approved serotonin reuptake inhibitors (SSRIs). Conclusions: Arbaclofen did not meet the primary outcome of improved social avoidance in FXS in either study. Data from secondary measures in the child study suggests younger patients may derive benefit, but additional studies with a larger cohort on higher doses would be required to confirm this finding. The reported studies illustrate the challenges but represent a significant step forward in translating targeted treatments from preclinical models to clinical trials in humans with FXS

General Messenger Gauge Mediation

We discuss theories of gauge mediation in which the hidden sector consists of two subsectors which are weakly coupled to each other. One sector is made up of messengers and the other breaks supersymmetry. Each sector by itself may be strongly coupled. We provide a unifying framework for such theories and discuss their predictions in different settings. We show how this framework incorporates all known models of messengers. In the case of weakly-coupled messengers interacting with spurions through the superpotential, we prove that the sfermion mass-squared is positive, and furthermore, that there is a lower bound on the ratio of the sfermion mass to the gaugino mass.Comment: 37 pages; minor change

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.Seaside Therapeutics Inc

Simplified R-Symmetry Breaking and Low-Scale Gauge Mediation

We argue that some of the difficulties in constructing realistic models of low-scale gauge mediation are artifacts of the narrow set of models that have been studied. In particular, much attention has been payed to the scenario in which the Goldstino superfield in an O'Raifeartaigh model is responsible for both supersymmetry breaking and R-symmetry breaking. In such models, the competing problems of generating sufficiently massive gauginos while preserving an acceptably light gravitino can be quite challenging. We show that by sharing the burdens of breaking supersymmetry and R-symmetry with a second field, these problems are easily solved even within the O'Raifeartaigh framework. We present explicit models realizing minimal gauge mediation with a gravitino mass in the eV range that are both calculable and falsifiable.Comment: 31 pages, 4 figures, references added, minor change